In our Department we have studied the first line treatment of 90 stage IIIA-IV @entity1149 @entity1 using @entity136 / @entity900 combination. Thirteen cases have been unevaluable for various reasons. At the time of evaluation the planned 4 cycles have been delivered to 38% of @entity1 (34/90). The PR was 39% (30/77), the CR was 2.6% (2/77) while the ORR was found to be 41% (32/77). 226 treatment cycles have been evaluated for side effects. There was no treatment-induced @entity204 in this series. CTC grade 3-4 @entity1398 occurred in 5.7% of the cycles and only in 2 cases combined with fever. CTC grade 3-4 @entity882 occurred in 4.4% of the cycles but only one @entity1 required platelet suspension administration. Grade 3-4 @entity417 developed in 3.5% of the cycles where 5 cases have been treated with RBC concentrate while 3 cases with erythropoietin. Complete @entity1665 occurred in 6 @entity1 but 3 of them received brain irradiation as well. CTC grade 3-4 @entity390 and @entity391 occurred in 4.4 and 3% of the cycles, respectively, but rehydration was only necessary in 3% of the cycles. Delay of the therapy due to hematological @entity137 or @entity391 occurred in 8% of the cycles but did not last longer than 2 weeks. Severe CTC grade 3-4 nephrotoxicity did not occur in this study while grade 1-2 elevation of serum @entity1011 level was found in 1.7% of the cycles. We have concluded that the @entity136 / @entity900 combination is a safe outpatient modality for the first line treatment of advanced @entity1149 @entity1 .

[ @entity136 - @entity900 combination in the first line treatment of XXXX . Our experience and analysis of safety].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
